Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy
Biotech
Sarepta's next DMD drug seems to get the job done in phase 2
Sarepta's next Duchenne muscular dystrophy med seems to be doing the job of spurring dystrophin expression. But does it matter given prior approvals?
Annalee Armstrong
Jan 29, 2024 10:49am
Pfizer’s DMD gene therapy now ‘main game in town,' CSO says
Oct 31, 2023 2:28pm
FDA questions benefits, risks of Sarepta DMD gene therapy
May 10, 2023 11:02am
In a U-turn, FDA orders AdComm for Sarepta's DMD gene therapy
Mar 17, 2023 6:29am
Hansa touts phase 2 data of one-trick pony transplant therapy
Nov 28, 2022 3:35pm
Solid Bio hopes to fortify itself after absorbing AavantiBio
Sep 30, 2022 10:30am